Clinical trials: Recurrent Endometrial Carcinoma, open to volunteers
Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous…
- Conditions
- Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03968406
- Testing
- Quality-of-Life Assessment, Radiation Therapy, Talazoparib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer, ARID1A Gene Mutation
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
The purpose of this research study is to see if the combination of study drugs avelumab and M1774 is effective and safe for participants with endometrial cancer.
- Conditions
- Endometrial Cancer, ARID1A Gene Mutation, Recurrent Endometrial Carcinoma
- Trial name
- NCT06518564
- Testing
- Avelumab, M1774
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Panagiotis Konstantinopoulos, MD, PhD
Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II…
- Conditions
- Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT06855706
- Testing
- Behavioral Intervention, Best Practice, Biospecimen Collection
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Roswell Park Cancer Institute
Endometrial Cancer, Endometrioid Tumor
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
- Conditions
- Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor
- Trial name
- NCT05997017
- Testing
- nab-sirolimus
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Aadi Bioscience, Inc.
Ovarian Cancer Recurrent, Endometrial Cancer Recurrent
A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
This is a non-interventional, real-world study divided into two parts: a retrospective study and a prospective study. The main question it aims to answer is: Will genomic sequencing and molecular tumor boards lead to clinical…
- Conditions
- Ovarian Cancer Recurrent, Endometrial Cancer Recurrent, Cervical Cancer Recurrent
- Trial name
- RWS-MTB (NCT06781151)
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Endometrial Cancer, Recurrent Endometrial Carcinoma
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
The goal of this study is listed below. Part A (Safety Run-in Phase) : To determine feasibility of pembrolizumab and nesuparib combination as maintenance therapy in patients with MMR-proficient advanced and recurrent endometrial…
- Conditions
- Endometrial Cancer, Recurrent Endometrial Carcinoma, Endometrial Carcinoma, Gynecologycal Cancer
- Trial name
- PENELOPE (NCT06502743)
- Testing
- Nesuparib, Pembrolizumab
- Where
- 6 sites in South Korea
- Volunteers
- 92 people
- Sponsor
- Yonsei University
Recurrent/Metastatic Endometrial Cancer
Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial
This study takes investigator-assessed Progression-Free Survival (PFS) as the primary endpoint, with plans to enroll 140 patients with advanced recurrent/metastatic endometrial cancer in a 1:1 ratio, randomized into an…
- Trial name
- A-CAPE (NCT06771154)
- Testing
- Adebelimab Combined with Apatinib, Adebelimab
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Peking Union Medical College Hospital
Recurrent or Metastatic Endometrial Cancer
QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer
the investigators planned to evaluate the efficacy and safety of QL1706 in combination with chemotherapy as first-line systemic therapy in approximately 26 patients with newly diagnosed recurrent or metastatic endometrial cancer…
- Trial name
- NCT06751277
- Testing
- QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706
- Where
- China
- Volunteers
- 26 people
- Sponsor
- xiang yang
Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
- Trial name
- NCT06522828
- Testing
- SSGJ-707, carboplatin, paclitaxel
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Stage IV Ovarian Cancer, Testis Cancer, Refractory
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced…
- Conditions
- Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent, CAR NK
- Trial name
- NCT05410717
- Testing
- Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Endometrial Carcinoma, TP53 Mutation
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial…
- Conditions
- Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic
- Trial name
- NCT06413992
- Testing
- Fluzoparib, Camrelizumab, paclitaxel (albumin bound)
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Endometrial Cancer Stage III, Endometrial Cancer Stage IV
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
- Conditions
- Endometrial Cancer Stage III, Endometrial Cancer Stage IV, Endometrial Cancer Recurrent
- Trial name
- PROMOTE (NCT03621904)
- Testing
- Hormonal Antineoplastics
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Radboud University Medical Center